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1 
A B S T R A C T   
The quantitative description of the interactions of uranium with blood serum components is of 
high relevance for a rational design of molecules suitable for in vivo chelation of uranium. We 
have determined the stability constants for the complexation of U(VI) with human serum 
transferrin and albumin by Time Resolved Laser Induced Fluorescence Spectroscopy and 
Difference Ultraviolet Spectroscopy. Both proteins interact strongly with U(VI), forming 
ternary complexes with carbonate acting as a synergistic anion. Together with literature data 
describing the interaction of U(VI) with low molecular weight inorganic and organic serum 
components, the speciation of U(VI) in blood serum was calculated. In agreement with 
published experimental data, the model calculation shows that complexation with proteins and 
carbonate ion governs U(VI) speciation; 35 % of U(VI) is bound to proteins and 65 % to 
carbonate. Among the protein pool, albumin is the main protein interacting with U(VI). In 
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addition, the results show that Ca(II) must be considered in the model as a competitive metal 
ion with respect to U(VI) for binding to albumin surface sites. Based on these findings several 
promising molecules for in vivo chelation of 230U could be identified.  
 
KEYWORDS: 230U, targeted alpha therapy, speciation, albumin, transferrin 
 
1. Introduction 
 
The principle of targeted alpha therapy (TAT) is based on the stable binding of alpha 
emitting radionuclides to cancer selective carrier molecules, such as antibodies or peptides, 
via bifunctional chelating agents (BCAs). Due to the short range (< 100µm) and the high 
linear energy transfer (≈100 keV/µm) of alpha radiation in human tissue, TAT allows to 
selectively deliver a highly cytotoxic radiation dose to targeted cells while sparing 
surrounding healthy tissue [1]. The alpha emitter 230U (t1/2 = 20.8 d) is a promising novel 
radionuclide for application in targeted alpha therapy of cancer [2-4]. For safe therapeutic 
application of 230U in targeted therapy, a chelating agent is required to link the radiometal to 
biological carrier molecules in a stable manner, since release of the alpha emitter from the 
radioconjugate in vivo might cause toxicity to normal organs.  Due to the relatively long half-
live of 230U of 20.8 days, the radioconjugate should show high stability over extended time 
periods. Ideally a suitable chelating agent should form uranium complexes of higher stability 
than ligands competing for uranium complexation under physiological conditions, such as 
carbonate, phosphate and proteins [5-7]. In order to evaluate the potential of candidate 
molecules for uranium chelation, in particular with respect to the stability of their uranium 
complexes in vivo, a full thermodynamic description of the interaction of uranium with 
competing ligands present in human body fluids, and in particular in blood serum, would be 
highly desirable. Certainly a quantitative speciation of uranium under physiological 
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conditions is also of high relevance for the understanding of toxicological effects of uranium 
as well as for the development of effective decorporation agents for uranium [5,8].  
Hexavalent U(VI) is the most stable oxidation state of uranium under physiological 
conditions [8]. It has been reported that U(VI) in the blood stream is forming complexes with 
carbonate and serum proteins, in particular with albumin and transferrin [7,9-11]. The 
thermodynamic parameters describing the interaction between U(VI) and relevant low 
molecular weight inorganic and organic ligands have been extensively studied and are rather 
well known [12,13]. However, the interaction between U(VI) and serum proteins is still a 
subject of discussion with respect to the nature of the interacting proteins [11,14], the 
quantitative description of the interaction [5] and the coordination environment of U(VI) [15], 
in particular with respect to the possible presence of the carbonate ion in the coordination 
sphere [7,14,15].  
Human serum albumin (HSA) is the most abundant protein in human blood plasma at a 
concentration of 30 to 50 g/L and comprises about half of blood serum protein. The 
interaction of uranium and HSA has been studied as early as 1948 by Guzman Barron et al. 
[16] using ultrafiltration. The authors report the reversibility of uranium binding to HSA and 
the influence of carbonate and citrate as competing ligands. No further thermodynamic 
analysis was performed. Chevari et al. [17] report a conditional stability constant of log K=10 
for the binding of uranium to HSA at pH=6 using a Shubert-type method [18], while Duff et 
al. [19] have determined conditional stability constants of log K = 1.6*107 M-1 and log K = 
2.8*105 M-1 for the binding to high-affinity and low-affinity sites at pH 5.5 using isothermal 
titration calorimetry.  
Human serum transferrin (HSTF) is an iron binding single-chain glycoprotein with a 
molecular mass of 79570 Da, containing 679 amino acids and consisting of two structurally 
related lobes referred to as N and C lobe. Each lobe is further divided into two subdomains by 
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a cleft, with each cleft housing a metal binding site. Metal binding to HSTF is generally 
facilitated through concomitant binding of carbonate as a synergistic anion [20]. The 
concentration of HSTF in serum is ca. 2.5 g/L, where about 30% are saturated with ferric ion. 
HSTF is also the primary serum transport agent of a large number of tri- and tetravalent metal 
ions [21]. Stevens et al. [9] reported that U(VI) in blood plasma of beagles injected with 
uranium citrate was present as 60% carbonate complex and 40% protein bound, with most of 
the protein-bound fraction presumably being associated with transferrin. The binding of 
uranium(VI) to HSTF has been studied by Scapolan et al. [10] using time-resolved laser-
induced fluorescence spectroscopy (TRLFS) at physiological pH. The formation of a 2:1 
complex of U(VI):HSTF has been reported, with an overall conditional stability constant of 
log K = 16. Sun et al. [22] have developed a correlation of the overall metal-binding constant 
of HSTF with the first metal hydrolysis constant, leading to a value of log K = 14.7 for the 
U(VI)-HSTF complex. This correlation was further refined by Ansoborlo et al. [6] through a 
critical assessment of the metal ion hydrolysis constants and the consideration of two 
individual binding sites, predicting values of log K = 14.1 and 12.6 for the C and N lobe, 
respectively. Vidaud et al. [15] have studied the structural properties of HSTF complexes of 
U(VI), and propose the existence of two binding sites, where U(VI) is coordinated under 
participation of two tyrosine residues. 
To our knowledge, thermodynamic data describing the complexation of uranium by HSA 
or HSTF applicable to a wide variety of body fluid compositions have not been reported to 
date. In this work we have determined the stability constants for the complexes of U(VI) with 
HSA and HSTF using TRLFS and Difference Ultraviolet Spectroscopy (DUS). Based on 
these parameters and including literature data of thermodynamic constants of U(VI) 
complexation with low molecular weight organic and inorganic ligands, a model calculation 
was performed to describe U(VI) interactions in human blood serum in a bottom-up approach. 
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The reliability of the simulation was assessed by comparison with published experimental in 
vitro speciation results [9,11,17]. To identify promising molecules for in vivo chelation of 
230U, the serum stability of several U(VI) chelate complexes was simulated. 
 
2. Materials and methods 
2.1. Reagents 
Human serum transferrin (apo-transferrin human ≥ 98 %, Sigma) was used as received 
or purified by size-exclusion chromatography on a PD-10 column using 0.1 M NaCl/0.05 M 
HEPES at pH 7.4 as an eluent. No difference in complexation was observed between purified 
and non-purified HSTF and no distinction was made in the following. HSTF concentration 
was determined spectrophotometrically at λ = 280 nm using 93,000 cm-1 M-1 as a molar 
extinction coefficient [23]. Human serum albumin (albumin from human serum ≥ 96 %, 
Sigma, mol wt 66,478 Da by calculation) was used as received. U(VI) stock solution was 
prepared by dilution of a standard solution (SPEX CertiPrep® Single-element Solution 
Standard, [U] = 1000 μg/mL, 2 % HNO3) with addition of sodium hydroxide to obtain a final 
concentration of 1 × 10-3 M at pH ~ 3. All other chemicals were reagent grade. HSTF, HSA 
and carbonate stock solutions were freshly prepared before use. Solutions were prepared with 
ultrapure water (MilliQ, 18 MΩ.cm) and pH measurements were performed using a Lab850 
pH meter combined with a micro electrode (Schott, Germany). 
 
2.2. Sample preparation 
All experiments were performed in solution of pH 7.4 ± 0.1 and ionic strength 0.1 (NaCl) 
buffered with 2 × 10-3 M HEPES at room temperature (23 ± 2 °C). Experiments in the absence 
of carbonate were performed in a glove box under 100% nitrogen atmosphere. Samples in the 
carbonate system were freshly prepared and kept closed to prevent equilibration with 
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atmospheric CO2. Irrespective of the system studied, equilibrium was shown to be established 
rapidly, i.e. in less than 20 minutes. During this time period, the concentration of carbonate in 
the closed system is considered to be constant. The experimental conditions are summarized 
in Table 1. 
 
2.3. Time Resolved Laser induced Fluorescence Spectroscopy (TRLFS)  
Details concerning the spectroscopic device as well as details on how spectroscopic data 
were obtained are described in [24]. U(VI) was excited at 430 nm with a laser intensity of 
about 3 mJ. As shown in Figure 1A, complexation of U(VI) by HSTF reaches equilibrium in 
less than 20 minutes and leads to a complete extinction of the fluorescence signal. Under 
given experimental conditions, the percentage of U(VI) not bound to HSTF can thus be 
determined according to Eq. (1): 
totFI
FI))VI(U%( =            (1) 
where FItot and FI correspond to the fluorescence intensity measured before and after addition 
of HSTF, respectively. The applicability of the method is limited in the presence of high 
carbonate concentrations, since carbonate complexes of U(VI) also do not emit fluorescence 
[10]. 
 
2.4. Difference ultraviolet spectroscopy (DUS)  
DUS is the most widely used technique to evaluate metal binding to HSTF [20]. UV-
spectra were recorded using an Ultrospec™ 2100 pro UV/Visible spectrophotometer. Metal 
complexation was evaluated from the absorbance measurements after addition of the metal 
using the difference spectra of the metal-protein complexes vs. unmetallated apo-protein. 
Either the peak height or the peak area in the range 235-271 nm were used to describe and 
quantify U(VI)-HSTF interaction. The main advantage of the method is that is the absorbance 
 7
signal of HSTF is not influenced by the presence of other ligands which may interact with 
U(VI) (e.g. carbonate). The interaction of HSA with U(VI) was studied using HSTF as a 
competitive agent [25]. 
 
2.5. Modelling the binding between U(VI) and proteins 
Several models can be used to describe the interactions between U(VI) and proteins. The 
simplest model (model 1) considers the metal ion interaction with the protein as a global 
reaction, without considering the possibility that several binding sites of different affinity may 
exist. Furthermore, the metal ion speciation in solution, i.e. the species distribution between 
U(VI) and low molecular weight ligands is not taken into account. Equilibrium constants 
derived from this model represent conditional constants and can only be applied to the 
experimental conditions from which they have been obtained (i.e. pH, medium composition, 
protein concentration range). This model was used by Scapolan et al. [10] to describe U(VI) 
interaction with HSTF according to Eq.(2): 
HSTF U HSTFU2 2
→
←+          (2) 
The obtained constant cannot be extrapolated to blood serum conditions, since the constant 
was determined in the presence of a lower concentration of carbonate (2 × 10-4 M) compared 
to the carbonate concentration of blood serum (2.5 × 10-2 M). This simple model was also 
used by Chevari et al. [17] to describe the interaction of U(VI) and HSA considering the 
formation of a 1:1 complex at pH 6, consequently also not allowing to apply the constant to 
serum conditions. 
A more complex model (model 2) takes into account the metal ion speciation and the 
possible presence of different binding sites at the protein surface: 
i) teprotein(si- U i) teprotein(si  U →←+        (3) 
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The description of the interaction remains however incomplete as the functional groups 
implied in the complexation are not explicitly differentiated. Given that the pH and ionic 
strength are kept constant, the model can be used as a predictive tool to describe the 
interaction in different media. This is the model generally used to describe metal-HSTF 
interactions. Metal ion speciation in solution is often simplified and taken into account in the 
calculation by introducing a strong complexing agent having a known equilibrium 
complexation constant for U(VI) (see [20] and quoted references). 
When a microscopic model (model 3) is used, interactions at the molecular level are 
converted to reactions according to the law of mass action and thermodynamic parameters can 
be derived. To our knowledge such a model has never been used to describe metal protein 
interactions considering the lack of spectroscopic data characterizing the interaction and 
considering the complexity to describe metal ion interactions with organic polyelectrolytes 
(e.g., see the case of natural organic matter [26]). 
For the purpose of our study, only models 2 and 3 were applicable and were used to describe 
the interaction of U(VI) with HSA and HSTF, respectively. The interaction of U(VI) with 
proteins was described using a surface complexation model in analogy to studies investigating 
the interactions of metal ions with natural organic polyelectrolytes (see e.g. [27]) as detailed 
below.  
 
2.5.1. Modelling the binding of U(VI) to HSTF  
HSTF was shown to display two structurally related but slightly different binding sites 
( S HSTF 1≡  and SHSTF 2 ≡ ), each binding site interacting with U(VI) under the participation 
of two tyrosine groups [15]. The binding sites react with water according to Equation (4): 
+−→
←
−
+−→
←
+≡+≡
+≡+≡
OHSHSTFOHSHHSTF
OHSHHSTFOHSHHSTF
3
2
1,221,2
31,2221,2       (4) 
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The pKa value associated to the Tyr188 residue was recently measured by 2D NMR-pH 
titration as 6.9 (0.5 M KCl) [28]. Based on the Davies equation we recalculated a value of 7.2 
for zero ionic strength [29] for introduction into the calculation code. For the other tyrosine 
residue Tyr95, no data is available and a pKa value of 10 (10.2 at zero ionic strength), 
associated with a “normal” tyrosine residue, was used [30]. We assume that the species 
interacting with the binding sites in the absence of carbonate is UO22+, i.e. there are no ternary 
complexes formed with other anions present in the medium (OH-, Cl-, NO3-). The reaction is 
then described  by Eq.(5): 
22,1
2
2
2
2,1 SUOHSTFUOSHSTF ≡+≡
→
←+−        (5) 
Each lobe of transferrin contains two tyrosine Fe(III) binding sites that are remarkably similar 
([20] and quoted references). This was also observed to a certain extent with U(VI): Vidaud et 
al. demonstrated that both tyrosines at the iron binding site are involved in uranium binding 
[15]. Irrespective of the metal ion considered [20], the stability constants for interaction with 
the binding sites differ by approximately one unit in their log K value, the difference being 
probably related to outer-sphere effects [25]. This ratio of 10 was set as a fixed parameter in 
the fitting of our experimental data. In the presence of carbonate, a ternary complex may be 
formed [7,15] according to Eq.(6): 
n2
n322,1n
2
3
2
2
2
2,1 )CO(SUOHSTF)CO(UOSHSTF
−→←−+− ≡++≡      (6) 
No electrostatic effects were considered in the calculation and the parameters must be 
considered as operational. 
 
2.5.2. Modelling the binding of U(VI) to HSA  
Metal binding to HSA is of complex nature, characterized by multiple binding sites whose 
affinity and binding capacity are varying (e.g. [31-33]). The microscopic model 3 is therefore 
not applicable and model 2 was used instead. To describe the interaction of U(VI) with HSA 
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in blood, Chevari et al. [34] proposed an exchange process between Ca(II) and U(VI). 
According to [35], about 70% of calcium in the blood serum is complexed with low molecular 
weight molecules, while the rest is bound to proteins. The protein bound fraction of calcium 
can be considered as attached mainly to HSA: Ca is known to interact with HSA [31,32] and 
Ca(II) interaction with HSTF is expected to be negligible; its interaction is weak [20] and 
protein-bound Ca concentration represents about 8 % of the total HSTF concentration. Based 
on a typical serum composition [6], this leads to an average of 0.7 Ca atoms bound per HSA 
molecule. The total number of binding sites (Ntot) reported in the literature for Ca on HSA 
varies [32] with the highest value reported as 30 [31]. The value depends on the HSA/metal 
ratio: for a given data set, Ntot reflects the total molar binding ratio of the predominant 
calcium binding class and not the maximal molar binding ratio [32]. Anderson showed, 
however, that Ca interaction under physiological conditions is governed by the interaction 
with a strong site [31]. A site of stronger affinity was as well considered for other divalent 
metal ions like VO2+ [33] and Ni2+ [36]. Glennon & Sarkar showed that both Cu2+ and Ni2+, 
although presenting different coordination properties, interact with the same HSA binding site 
[36]. Based on these considerations, our model considers the existence of only one binding 
site at the HSA surface which interacts with both U(VI) and Ca(II) cations, according to 
Eq.(7): 
2n2
n32n
2
3
2
2
22
)(COSUOHSA)(COUOSHSA
SCaHSACaSHSA
−→
←
−+
+→←+
≡++≡
≡+≡
     (7) 
Contrary to the equilibrium generally considered in model 2 (Eq. (3)), the possible formation 
of ternary complexes of U(VI) with HSA and carbonate must be considered under serum 
conditions (see comments above). All calculations were performed using the simulation code 
PHREEQC, a geochemical modelling code for aqueous systems [37]. Stability constants for 
metal ion complexation in solution were taken from NEA-OECD [12] (complexation of 
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U(VI) with inorganic ligands), NIST [13] (U(VI) and citrate) and Llnl.dat [37] (Ca 
complexation) thermodynamic databases. 
 
3. Results and discussion 
 
3.1. Binding of U(VI) to proteins 
3.1.1.Binding of U(VI) to HSTF.  
TRLFS experiments performed in the absence of carbonate show a significant 
complexation of U(VI) by HSTF at pH 7.4, i.e. 76 % of U(VI) were found to be bound to 
HSTF in the presence of a 4-fold excess of HSTF over U(VI). The stability constants 
describing the interaction (Eq. (5)) were found to be log K = 12.4 and log K = 11.4 (I=0) for 
the high-affinity and low-affinity site at zero ionic strength, respectively (Table 2). This set of 
constants was used to calibrate the UV-spectroscopy method, i.e. to relate the area of the 
absorption peak at 242 nm with the amount of the complexed species U(VI)-HSTF. As this 
absorption band is linked to the interaction of the metal ions to the phenolic groups of the 
tyrosine residues [10,20], we assume that the extinction coefficient is not affected by the 
nature of other ligands coordinated in the first coordination sphere of U(VI), i.e. the 
calibration parameters are applicable also when the synergistic carbonate ion is bound (Eq. 
(6)). 
The experimental data obtained in the presence of carbonate are presented in Figure 1B. 
The values obtained by TRLFS and DUS are in good agreement. The fraction of U(VI) bound 
to HSTF increases with increasing carbonate concentration up to a total carbonate 
concentration of ca. 2 × 10-4 M, indicating the formation of a ternary complex in solution, 
with carbonate acting as synergistic anion according to Eq. (6). At higher concentrations of 
total carbonate, the fraction of HSTF-bound U(VI) decreases, due to increasing competition 
of carbonate with HSTF for U(VI) complexation. The complete set of experimental data could 
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be well described considering one carbonate ion bound to U(VI) with stability constants of 
log K = 20.8 and log K = 19.8 (I=0) for the ternary complexes formed at the high-affinity and 
low-affinity site (Table 2). The data could not be fitted without considering the formation of 
ternary complexes. Under blood serum conditions, the ternary complexes will be the 
dominant species, i.e. the binary U(VI)-HSTF complex formed according to Eq.(5) will not be 
formed. 
The results of a titration of HSTF with U(VI) are presented in Figure 2A. Increasing 
metallation of HSTF leads to an increase of absorbance signal that could be extrapolated by 
non-linear regression to a plateau at Δε = (30 ± 2) × 103 M-1 cm-1 at 242 nm associated with 
the formation of a 2:1 U(VI):HSTF complex. This value is in excellent agreement with the 
values previously reported for U(VI) [15] and for other metal ions [20,38]. The increase of 
absorption observed above the theoretical saturation level (2 U(VI) for one HSTF molecule, 
r=2) is due to the presence of uncomplexed U(VI) as the chosen experimental conditions do 
not allow for complete complexation of U(VI) by HSTF. 
The reliability of the determined stability constants describing the formation of the ternary 
complexes, derived from the experimental data presented in Figure 1B, relies on the reliability 
of the constants characterizing the carbonate complexation of U(VI) taken from [gui03]. 
Therefore, to test the obtained constants, they were used to calculate U(VI) speciation in a 
simplified system simulating blood serum, i.e. containing HSTF and carbonate ion (4 × 10-4 
M) as a function of concentration of citrate, a well known strong complexing agent for U(VI) 
[6] and the calculated results were compared to experimental data. Considering the relatively 
large size of the citrate molecule, we assume that the synergistic carbonate ion bound to 
U(VI) with HSTF will not be exchanged by citrate. The experimental data, representing the 
percentage of U(VI) bound to HSTF determined by spectrophotometry as a function of citrate 
concentration, are presented in Figure 2B. As shown by the solid line, a good agreement 
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between the prediction and the experiment is obtained showing the reliability of our stability 
constants for HSTF complexation of U(VI). 
According to the literature, there is a good correlation between the strength of metal 
binding to transferrin and the stability constant for hydroxide binding to the same metal ion 
[6,20]. Compared to the values of log K = 14.1 and 12.6 derived from this correlation for 
strong and weak sites, respectively [6], the values determined in this work are approximately 
one order of magnitude lower (see Table 2). This might be explained by the fact that the 
binding sites of HSTF are ideally pre-organized to complex spherical cations in three 
dimensions like Fe(III), whereas complexation of the linear uranyl cation must account for its 
preferred equatorial coordination. This is in agreement with the recent work of Vidaud et al. 
[15] who showed that the coordination with U(VI) cannot be compared with that of Fe(III) 
and that the participation of the His249 ligand in the coordination sphere of uranyl can be 
excluded. 
 
3.1.2.Binding of U(VI) to HSA.  
The binding between U(VI) and HSA was studied using a displacement method in the 
presence of HSTF [25]. This method is applicable because no significant absorption of the 
U(VI)-HSA complex occurs in the HSA concentration range explored (< 4×10-5 M) that could 
interfere with the measurement of the absorbance signal of the U(VI)-HSTF complex. This 
observation indicates that HSA does not interact with U(VI) via tyrosine groups, in agreement 
with the nature of the interaction of HSA with Cu(II) and Ni(II) at the strong binding site [36]. 
The system with HSTF and HSA competing for U(VI) complexation is also a good 
representation of the situation in blood serum. The concentration of carbonate ion in the 
system was varied to assess its role for the coordination of U(VI) with HSA. It was found that 
the data at equilibrium are not affected by the addition order of the components, indicating 
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that the interaction of U(VI) with the two proteins is reversible. The experimental results are 
shown in Figure 3. In order to obtain a good fitting of the experimental data, the formation of 
a ternary HSA-U(VI)-carbonate complex needs to be taken into account at higher 
concentrations of carbonate (Fig. 3B). The stability constants were determined as log K = 
10.8 (I = 0) for U(VI)-HSA and log K = 17.7 (I = 0)  for U(VI)-HSA-carbonate as 
summarized in Table 2. 
Overall our experimental data on the interaction of U(VI) with HSTF and HSA obtained 
in the presence of carbonates could be well described by considering the formation of ternary 
complexes between the protein, one carbonate ion and U(VI). The occurrence of ternary 
complexes is in agreement with general understanding of metal binding to HSTF [20,21], and 
agrees well with the reports of Van Horn et al. and Huang et al.  [7,14] on the binding of 
U(VI) to proteins. However, they propose the involvement of two carbonate ions in the U(VI) 
coordination sphere when bound to proteins or peptides. To the best of our knowledge, there 
is no experimental proof to support this statement, but it is rather an assumption based on the 
presence of the U(VI)-bis-carbonato complexes in blood serum. Our data show that both HSA 
and HSTF have a strong but similar affinity for U(VI). Indeed, if the experimental data are 
analysed based on model 2 (Eq. (3)), the stability constants obtained for U(VI) complexation 
are identical for both proteins (see Table 2). 
 
3.2. Simulation of U(VI) speciation in the blood serum and comparison with in vitro 
speciation results 
3.2.1. Serum composition.  
The aim of our model calculation was to simulate the speciation of trace concentrations of 
U(VI) under serum conditions, where U(VI) may interact with all types of complexing agents 
present in the serum, i.e. inorganic ligands, organic ligands and proteins. Considering the 
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complexity of the biological medium, simplifications were made considering that the 
interaction strength of given serum components with U(VI) will depend on their 
concentrations as well as the equilibrium complexation constants. All relevant inorganic 
ligands were taken into account (hydroxide, carbonate, phosphate, chloride, sulphate) using 
the constants given in [12]. Concerning low molecular weight organic components, only the 
citrate ion was considered as it is present in human serum at a relatively high concentration 
(1.6 × 10-4 M) and has a relatively high stability constant for U(VI) complexation [6]. 
Although recent work of Vidaud et al. showed that a number of proteins can bind U(VI) [11], 
only HSA and HSTF were considered in the present study as they constitute the predominant 
metallo-proteins present in high concentrations in human blood serum [6]. 
In addition, a possible competition with other metal ions present in blood serum has to be 
taken into consideration. Also in this case simplifications are necessary. Given the high 
difference in log K values (about 10 orders of magnitudes), we can safely consider that trace 
concentrations of U(VI) can not compete with Fe(III) for HSTF binding sites. The number of 
available HSTF binding sites was therefore set to 70 % of the total capacity, corresponding to 
the fraction of HSTF not loaded with ferric ion [20]. Another cation that has to be taken into 
account is Ca(II) as it is present in blood serum in relatively high concentrations [35] and it is 
known to strongly interact with HSA [32].  
 
3.2.2. Ca interaction with HSA 
In previous studies, model 1 was used to describe the interaction of calcium with HSA 
[32]. As discussed in the modelling part, this model is not applicable for the purpose of the 
present study, i.e. the competition between Ca(II) and U(VI) for the strong site must be 
explicitly described. For this purpose, experimental data obtained by Besarab et al. [32] in 
conditions similar to those found in blood serum were re-evaluated according to Eq.(7). To 
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characterize Ca(II) interaction with the strong site on HSA, only the experimental data where 
less than one Ca(II) is bound per HSA molecule were taken into account, resulting in a value 
for log K = 4.2 (see SM-1). Based on this stability constant together with thermodynamic data 
for calcium complexation taken from Llnl.dat [37], the species distribution of calcium in 
blood serum [6] was calculated. The calculation results in 34 % of Ca bound to HSA and 66 
% "non-protein bound", i.e. 49 % in the ionic form, 8 % complexed with citrate, 5 % as a 
carbonato complex, 2 % bound to phosphates and the remaining 2 % being distributed 
between other species. This indicates that the stability constant for Ca(II)-HSA complexation 
is reliable since the calculation is in agreement with experimental data reported in [35], where 
67 ± 2 % of Ca is in ionic form or complexed with low molecular weight organic and 
inorganic molecules, while the remaining part is bound to the protein pool. 
 
3.2.3. Simulation of U(VI) speciation in human serum 
Based on the stability constants for U(VI) complexation by HSTF and HSA determined in 
this study, together with known thermodynamic parameters for complexation of U(VI) with 
low molecular weight organic and inorganic ligands, the species distribution of U(VI) in 
human blood serum was calculated. The model calculation shows that U(VI) speciation is 
governed by both the carbonate ion and the proteins. 65 % of U(VI) are complexed with CO32- 
as the bis- (3 %) and tris-carbonato (59 %) complexes, while the remaining fraction is bound 
to the protein pool, 28 % and 7 % with HSA and HSTF, respectively. Calcium has a 
significant effect on U(VI) speciation. Without considering the competition of Ca(II) for 
binding sites on HSA, approximately 70 % of U(VI) would be predicted to be bound to the 
protein fraction. In agreement with what is generally stated in the literature [6,7], both 
proteins (HSTF and HSA) and carbonate govern U(VI) speciation in blood serum at 
equilibrium. This is also supported by the experimental data reported by Chevari et al. and 
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Stevens et al. showing a ratio of carbonate vs. protein bound U(VI) in plasma of 64:36 and of 
60:40, respectively [9,34]. The agreement is less satisfactory when comparing our model 
calculation with the data obtained by Vidaud et al. [11]. From in vitro experiments they 
concluded that about 20 % of uranyl in serum is associated with the protein pool, whereas our 
simulation leads to a value of 35 %. 
In agreement with Chevari et al. [34], our simulation showed that the role of HSTF is 
minor and that binding of U(VI) to HSA is predominant. As both proteins display a similar 
strength for binding of U(VI), but HSA concentration in serum is one order of magnitude 
higher than HSTF concentration, 80% of protein bound U(VI) is associated with HSA 
compared to 20% of U(VI)-HSTF.  This is in contrast to the predominance of HSTF binding 
of U(VI) reported in [9], however, the authors do not provide detailed support of their 
statement.  
 
3.3. Chelating agents for application of 230U in targeted alpha therapy   
The modelling of the speciation of U(VI) in blood serum can be used to make predictions 
on the stability of potential U(VI)-chelate complexes under serum conditions and to select 
promising ligands for further testing and experimental validation of their stability in vitro and 
in vivo. For a simplified estimation, assuming the injection of 1 mg of 230U labelled antibody 
carrying one chelate per antibody molecule, the concentration of chelate in the blood pool will 
be initially in the range of 10-9 M. Taking into account the concentrations and stability 
constants of the competing ligands carbonate, HSA and HSTF, the model calculation shows 
that a chelate suitable for stable binding of 230U(VI) under serum conditions is required to 
have a stability constant for UO22+ of 1019 M-1 at physiological pH if >90 % of U(VI) should 
remain bound at equilibrium. However, chelating agents with lower stability constants could 
be useful in case their U(VI) complexes display a sufficiently high kinetic stability against 
 18
dissociation under serum conditions within the residence time of the radioconjugate in vivo. A 
large number of potential complexing agents for U(VI) have been reported in literature for a 
variety of applications, including the development of decorporation agents [8] and antibody 
based assays [39]. Based on their high stability constants for complexation of U(VI), the 
calixarene family [40], in particular calix[6]- and calix[8]-arene [41,42], appear promising. 
Calixarenes can easily be bi-functionalised [43] to establish the link to biological carrier 
molecules without modifying the functional groups available for the complexation. According 
to the work of Mullen et al. [44], the siderophore desferrioxamine B (DFO), that is already 
used for nuclear imaging when labelled with 89Zr(IV) [45], may as well be a good candidate. 
The authors report an equilibrium constant between UO22+ and the deprotonated ligand of 
1017.1 M-1 for an ionic strength of 0.1 M. Another promising molecule is the versatile ligand 
1,10-phenanthroline-2,9-dicarboylic acid (DCP) that has been shown to efficiently complex 
U(VI) in biological media [39]. The synthesis of a bifunctional derivative has been reported 
and a complexation constant between the deprotonated ligand and UO22+ exceeding 13 has 
been reported  [46].  
 
4. Conclusions  
The stability constants determined in this work for the complexation of U(VI) by HSA 
and HSTF allow to predict the speciation of U(VI) in human body fluids. The model 
calculations could be validated through experimental data obtained in blood serum and 
provide a realistic, qualitative and quantitative description of U(VI) behaviour. The model 
initially composed of 43 equilibrium equations could be simplified to only a few, describing 
the formation of bis- and tris- carbonato complexes of U(VI), the complexation of U(VI) with 
HSA and HSTF and taking into account the competition between Ca and U(VI) for binding to 
the strong site of HSA. 
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5. Abbreviations 
 
 
Targeted alpha therapy TAT 
Bifunctional chelating agents  BCAs 
Human Serum TransFerrin HSTF 
Human Serum Albumin; HSA 
Time Resolved Laser Fluorescence Spectroscopy TRLFS 
Difference Ultraviolet Spectroscopy DUS 
N-(2-HydroxyEthyl)Piperazine-N’-2-EthaneSulfonic acid  HEPES 
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Table 1: Interaction between U(VI) and proteins; methods and experimental conditions. 
Method Principle U(VI) HSTF carbonate concentration experiment Figure 
5x10-6 M 0 kinetic 1A 
TRLFS see Eq.( 1) 
0 - 2x10-3 M 1B 
0 - 3x10-2 M 
carbonate titration
1B 
2x10-4 M U(VI) titration 2A 
4x10-4 M 
competition with 
citrate ion  
(2x10-4-4x10-2 M) 
2B 
2x10-4 M 3A 
DUS 
absorption of 
U(VI)-HSTF 
complex at 
242 nm 
2x10-5 M 
2x10-5 M
2x10-3 M 
competition with 
HSA  
(3.10-6 - 5.10-5 M) 3B 
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Table 2: Quantitative description of U(VI) with HSTF and HSA and comparison with 
published data. 
 
Protein Equation Model  Site / interacting group log K Ref. Remarks 
Weak site 12 
13 
this work
14.3* [22] 
strong site 
14.1*Eq. (3) 2 
Weak site 12.6*
[6] 
carbonate 
concentration at 25 
mM 
Eq. (2) 1   16 [10] 
carbonate 
concentration at 0.1 
mM 
Tyr188 (both sites)   -7.2 [28] Eq. (4) 
Tyr95 (both sites)  -10.2 [30] 
strong site 12.4Eq. (5) 
weak site 11.4
strong site 20.8
HSTF 
Eq. (6)  
3 
weak site 
n=1 (CO32-) 19.8
this work
see experimental 
conditions in Table 1 
strong site 7.2 
Eq. (4) 3 weak site 5.4 [19] 
pH 5.5, normal CO2 
atmosphere 
Eq. (2) 1 _ 10 [17] pH=6, ionic strength fixed at 0.1 M  
Eq. (3) _ 13 
carbonate 
concentration at 25 
mM 
n=0 (CO32-) 10.8
HSA 
Eq. (7) 
2 
n=1 (CO32-) 17.7
this work
see experimental 
conditions in Table 1 
* extrapolated values 
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Figures captions 
 
 
Figure 1: Complexation of U(VI) by HSTF. Experimental conditions are summarized in 
Table 1. (A) Relative U(VI) fluorescence intensity measured as a function of the time after 
HSTF addition. (B) Complexation of U(VI) by HSTF as a function of carbonate 
concentration. The lines are calculated with the parameters given in Table 2 considering (solid 
line) or not-considering (dashed line) the formation of a ternary complex (Eq.(6)). 
 
Figure 2: Complexation of U(VI) by HSTF as a function of U(VI) (A) and citrate (B) 
concentrations. In Figure 2A, r represents the ratio between total U(VI) and HSTF 
concentrations. Δε is calculated from the absorbance of U(VI)-HSTF complex measured at 
240 nm divided by HSTF concentration. The lines are calculated with the parameters given in 
Table 2. For Figure 2B, an extinction coefficient of 3 × 104 M-1cm-1 characterizing the 2:1 
U(VI):HSTF complex is used. Experimental conditions are summarized in Table 1. 
 
Figure 3: Competition between HSTF and HSA for U(VI) in the presence of 2 × 10-4 M (A) 
and 2 × 10-3 M (B) of total carbonate. The system is pre-equilibrated before addition of HSTF 
(circle) or HSA (squares). Experimental conditions are summarized in Table 1. The lines are 
calculated with the parameters given in Table 2 considering (solid line) or not-considering 
(dotted lines) the formation of a ternary complex (Eq.(7)). 
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Figure 2 
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Figure 3 
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SUPPLEMENTARY MATERIAL 
 
 
 
SM-1: 
The Figure reports the experimental data given in [32] used to determine log K of Ca-HSA. 
They include the range of albumin concentration found in the blood serum and reflect the 
interaction of Ca with the strong site, where at equilibrium less than one Ca is bound per 
albumin molecule. The line was calculated using the parameters given in the main text. 
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